178 related articles for article (PubMed ID: 25057941)
41. Targeting of Both the c-Met and EGFR Pathways Results in Additive Inhibition of Lung Tumorigenesis in Transgenic Mice.
Stabile LP; Rothstein ME; Keohavong P; Lenzner D; Land SR; Gaither-Davis AL; Kim KJ; Kaminski N; Siegfried JM
Cancers (Basel); 2010 Dec; 2(4):2153-70. PubMed ID: 21390244
[TBL] [Abstract][Full Text] [Related]
42. Ephedrae herba stimulates hepatocyte growth factor-induced MET endocytosis and downregulation via early/late endocytic pathways in gefitinib-resistant human lung cancer cells.
Nishimura Y; Hyuga S; Takiguchi S; Hyuga M; Itoh K; Hanawa T
Int J Oncol; 2016 May; 48(5):1895-906. PubMed ID: 26983447
[TBL] [Abstract][Full Text] [Related]
43. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.
Nakade J; Takeuchi S; Nakagawa T; Ishikawa D; Sano T; Nanjo S; Yamada T; Ebi H; Zhao L; Yasumoto K; Matsumoto K; Yonekura K; Yano S
J Thorac Oncol; 2014 Jun; 9(6):775-83. PubMed ID: 24828661
[TBL] [Abstract][Full Text] [Related]
44. MicroRNA‑200a suppresses migration and invasion and enhances the radiosensitivity of NSCLC cells by inhibiting the HGF/c‑Met signaling pathway.
Du M; Wang J; Chen H; Wang S; Chen L; Xu Y; Su F; Lu X
Oncol Rep; 2019 Mar; 41(3):1497-1508. PubMed ID: 30569179
[TBL] [Abstract][Full Text] [Related]
45. Hepatocyte growth factor and HER2/neu downregulate expression of apoptosis-inducing factor in non-small cell lung cancer.
Chiang YY; Chow KC; Lin TY; Chiang IP; Fang HY
Oncol Rep; 2014 Feb; 31(2):597-604. PubMed ID: 24276579
[TBL] [Abstract][Full Text] [Related]
46. HGF induces EMT in non-small-cell lung cancer through the hBVR pathway.
Liu F; Song S; Yi Z; Zhang M; Li J; Yang F; Yin H; Yu X; Guan C; Liu Y; Liu Z; Wang J; Zhu D
Eur J Pharmacol; 2017 Sep; 811():180-190. PubMed ID: 28554854
[TBL] [Abstract][Full Text] [Related]
47. HGF and TGFβ1 differently influenced Wwox regulatory function on Twist program for mesenchymal-epithelial transition in bone metastatic versus parental breast carcinoma cells.
Bendinelli P; Maroni P; Matteucci E; Desiderio MA
Mol Cancer; 2015 Jun; 14():112. PubMed ID: 26041563
[TBL] [Abstract][Full Text] [Related]
48. [The mechanism of gefitinib resistance induced by hepatocyte growth factor in sensitive non-small cell lung cancer cells in vitro].
Xuan X; An C; Zhou C
Zhongguo Fei Ai Za Zhi; 2013 Jan; 16(1):1-6. PubMed ID: 23327866
[TBL] [Abstract][Full Text] [Related]
49. Interruption of hepatocyte growth factor signaling augmented oridonin-induced death in human non-small cell lung cancer A549 cells via c-met-nuclear factor-κB-cyclooxygenase-2 and c-Met-Bcl-2-caspase-3 pathways.
Liu Y; Shi QF; Qi M; Tashiro S; Onodera S; Ikejima T
Biol Pharm Bull; 2012; 35(7):1150-8. PubMed ID: 22791165
[TBL] [Abstract][Full Text] [Related]
50. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
[TBL] [Abstract][Full Text] [Related]
51. High EMT Signature Score of Invasive Non-Small Cell Lung Cancer (NSCLC) Cells Correlates with NFκB Driven Colony-Stimulating Factor 2 (CSF2/GM-CSF) Secretion by Neighboring Stromal Fibroblasts.
Rudisch A; Dewhurst MR; Horga LG; Kramer N; Harrer N; Dong M; van der Kuip H; Wernitznig A; Bernthaler A; Dolznig H; Sommergruber W
PLoS One; 2015; 10(4):e0124283. PubMed ID: 25919140
[TBL] [Abstract][Full Text] [Related]
52. The repression and reciprocal interaction of DNA methyltransferase 1 and specificity protein 1 contributes to the inhibition of MET expression by the combination of Chinese herbal medicine FZKA decoction and erlotinib.
Zheng F; Zhao Y; Li X; Tang Q; Wu J; Wu W; Hann SS
J Ethnopharmacol; 2019 Jul; 239():111928. PubMed ID: 31077779
[TBL] [Abstract][Full Text] [Related]
53. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
54. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.
Uramoto H; Yamada T; Yano S; Kondo N; Hasegawa S; Tanaka F
Anticancer Res; 2012 Sep; 32(9):3785-90. PubMed ID: 22993320
[TBL] [Abstract][Full Text] [Related]
55. Constitutive activation of met kinase in non-small-cell lung carcinomas correlates with anchorage-independent cell survival.
Qiao H; Hung W; Tremblay E; Wojcik J; Gui J; Ho J; Klassen J; Campling B; Elliott B
J Cell Biochem; 2002; 86(4):665-77. PubMed ID: 12210733
[TBL] [Abstract][Full Text] [Related]
56. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression.
Abounader R; Ranganathan S; Lal B; Fielding K; Book A; Dietz H; Burger P; Laterra J
J Natl Cancer Inst; 1999 Sep; 91(18):1548-56. PubMed ID: 10491431
[TBL] [Abstract][Full Text] [Related]
57. Signaling pathway involved in cyclooxygenase-2 up-regulation by hepatocyte growth factor in endometrial cancer cells.
Yoshizawa Y; Yamada Y; Kanayama S; Shigetomi H; Kawaguchi R; Yoshida S; Nagai A; Furukawa N; Oi H; Kobayashi H
Oncol Rep; 2011 Oct; 26(4):957-64. PubMed ID: 21687953
[TBL] [Abstract][Full Text] [Related]
58. Evidence that depletion of the sorting nexin 1 by siRNA promotes HGF-induced MET endocytosis and MET phosphorylation in a gefitinib-resistant human lung cancer cell line.
Nishimura Y; Takiguchi S; Ito S; Itoh K
Int J Oncol; 2014 Feb; 44(2):412-26. PubMed ID: 24297483
[TBL] [Abstract][Full Text] [Related]
59. The Involvement of Hepatocyte Growth Factor-MET-Matrix Metalloproteinase 1 Signaling in Bladder Cancer Invasiveness and Proliferation. Effect of the MET Inhibitor, Cabozantinib (XL184), on Bladder Cancer Cells.
Shintani T; Kusuhara Y; Daizumoto K; Dondoo TO; Yamamoto H; Mori H; Fukawa T; Nakatsuji H; Fukumori T; Takahashi M; Kanayama H
Urology; 2017 Mar; 101():169.e7-169.e13. PubMed ID: 28013036
[TBL] [Abstract][Full Text] [Related]
60. HGF/c-Met overexpressions, but not met mutation, correlates with progression of non-small cell lung cancer.
Gumustekin M; Kargi A; Bulut G; Gozukizil A; Ulukus C; Oztop I; Atabey N
Pathol Oncol Res; 2012 Apr; 18(2):209-18. PubMed ID: 21779788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
